Conference
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
Authors
Macaulay VM; Middleton MR; Eckhardt SG; Juergens RA; Stephens AW; Poondru S; McCarthy SP; Gadgeel SM
Volume
28
Pagination
pp. 3016-3016
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2010
DOI
10.1200/jco.2010.28.15_suppl.3016
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X